PATENT CLAIM ANALYSIS

Application Number: 16206694
Application Type: Utility
Filing Date: 2018-11
Publication Date: 2019-03
Patent Classification: ["424", "450000"]

Abstract:
Novel encapsulated umirolimus and umirolimus polymer conjugate formulations having enhanced permeability and retention at tumor sites. Also provided are methods for treating cancer by administering the umirolimus formulations.

Claim (Index 6):
The formulation of  claim 4 , further comprising cholesterol, wherein the phospholipid is PEGylated phospholipid is PEG-DSPE, the PC is HSPC, the umirolimus is present at the molar ratio of 0.1-2%, and a molar ratio between the PEGylated phospholipid, the PC, and the cholesterol is 55-65:2-10:20-40.

Metadata:
- Claim Count in Document: 20.0
- Percentile: 98.0
- Lexical Diversity: 1.2
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['14093876', '14765620', '13916129', '12761588', '12731781']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7039211015954875
- 35 USC 102 Novelty (BERT): 0.5037392917325696
- Combined Prediction Score: 0.6839029206091958
- Mean Citation Score: 219.67006
- Max Citation Score: 284.49216
- Similarity Product: 229.2593719482421

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test